Loading...
Derniers dépôts
-
Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud, Marie Attard, Claire Bournaud, et al.. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131 I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated thyroid Cancer. Clinical Cancer Research, 2023, 29 (13), pp.2401-2409. ⟨10.1158/1078-0432.CCR-23-0046⟩. ⟨inserm-04552345⟩
-
Grégoire Marret, Stéphane Temam, Maud Kamal, Caroline Even, Jean-Pierre Delord, et al.. Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity. Scientific Reports, 2023, 13, pp.22524. ⟨10.1038/s41598-023-49887-4⟩. ⟨hal-04543900⟩
-
Dana Hartl, Yann Godbert, Xavier Carrat, Stéphane Bardet, Audrey Lasne-Cardon, et al.. ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial. Trials, 2023, 24 (1), pp.298. ⟨10.1186/s13063-023-07294-0⟩. ⟨hal-04176626⟩
-
Renaud Descourt, Maurice Pérol, Gaëlle Rousseau-Bussac, David Planchard, Bertrand Mennecier, et al.. Efficacité et tolérance du brigatinib chez des patients pris en charge pour un cancer bronchopulmonaire non à petite cellules avec translocation ALK en France. Étude BRIGALK.. Congrès de pneumologie de langue française, Jan 2019, Marseille, France. ⟨10.1016/j.rmr.2018.10.039⟩. ⟨hal-02633916⟩
-
Renaud Descourt, Maurice Perol, Gaëlle Rousseau-Bussac, David Planchard, Bertrand Mennecier, et al.. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). Lung Cancer, 2019, 136, pp.109-114. ⟨10.1016/j.lungcan.2019.08.010⟩. ⟨hal-04529929⟩
-
Dana M Hartl, Yann Godbert, Xavier Carrat, Stéphane Bardet, Audrey Lasne-Cardon, et al.. Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial. Trials, 2023, 24 (1), pp.452. ⟨10.1186/s13063-023-07467-x⟩. ⟨inserm-04526673⟩
-
M Tonneau, R Nebbache, A Larnaudie, S Thureau, Y Pointreau, et al.. Management of head and neck carcinomas with synchronous or metachronous oligometastatic disease: Role of locoregional radiotherapy and metastasis-directed radiotherapy. Cancer/Radiothérapie, 2024, 28 (1), pp.83-92. ⟨10.1016/j.canrad.2023.03.004⟩. ⟨hal-04441453⟩
-
Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault de La Motte Rouge, Thierry Petit, et al.. Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast Cancer Research and Treatment, 2024, ⟨10.1007/s10549-024-07285-y⟩. ⟨hal-04495069⟩
-
Charlotte Demoor-Goldschmidt, Pascal Veillon, Maxime Esvan, Mathilde Leonard, Sophie Chauvet, et al.. A software tool to support follow-up care in a French childhood cancer cohort: construction and feasibility. BMC Cancer, 2024, Bmc Cancer, 24 (1), pp.130. ⟨10.1186/s12885-024-11857-y⟩. ⟨hal-04484217⟩
-
Enora Dolivet, Léopold Gaichies, Corinne Jeanne, Céline Bazille, Mélanie Briand, et al.. Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors. International Journal of Molecular Sciences, 2023, International Journal of Molecular Sciences, 24 (21), pp.16016. ⟨10.3390/ijms242116016⟩. ⟨hal-04481385⟩
-
Asmaa Janah, Charlotte Demoor-Goldschmidt, Florent de Vathaire, Nicolas Bougas, Jacqueline Clavel, et al.. Risk perceptions and health care use in the era of the COVID-19 pandemic in adults treated for childhood cancer. Supportive Care in Cancer, 2022, 30 (7), pp.6263 - 6271. ⟨10.1007/s00520-022-07035-0⟩. ⟨inserm-04438518⟩
-
Samia Chaouni, Alexandre Leduc, Frédéric Pouzoulet, Ludovic de Marzi, Frédérique Megnin-Chanet, et al.. Biological Effects of Scattered Versus Scanned Proton Beams on Normal Tissues in Total Body Irradiated Mice: Survival, Genotoxicity, Oxidative Stress and Inflammation. Antioxidants , 2020, 9 (12), pp.1170. ⟨10.3390/antiox9121170⟩. ⟨hal-04151956⟩
-
Stéphane Culine, Valentin Harter, Gwenaelle Gravis, Aude Fléchon, Christine Chevreau, et al.. Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Clinical Genitourinary Cancer, 2021, 19 (6), pp.554-562. ⟨10.1016/j.clgc.2021.08.005⟩. ⟨hal-03625944⟩
-
Jennifer Le Guevelou, Colin Debaigt, Esma Saada-Bouzid, Julien Viotti, Nazim Khalladi, et al.. Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREOSARC trial protocol.. BMJ Open, 2020, BMJ Open, 10, pp.e038391. ⟨10.1136/bmjopen-2020-038391⟩. ⟨hal-04346738⟩
-
Thomas Grinda, Alison Antoine, William Jacot, Paul-Henri Cottu, Thibault de la Motte Rouge, et al.. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort. European Journal of Cancer, 2023, 189, pp.112935. ⟨10.1016/j.ejca.2023.05.023⟩. ⟨hal-04205902⟩
Nombre de documents
176
Nombre de notices